| scholarly article | Q13442814 |
| P50 | author | Gregory S Calip | Q40651949 |
| Wan-Ju Lee | Q56854993 | ||
| P2093 | author name string | Stephen M Schwartz | |
| Henry G Kaplan | |||
| Judith A Malmgren | |||
| P2860 | cites work | Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia | Q24307594 |
| Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival | Q27022747 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Development of a comorbidity index using physician claims data | Q30623996 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project | Q33373051 | ||
| Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer | Q33561953 | ||
| Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005. | Q33938533 | ||
| Lineage-specific hematopoietic growth factors | Q33995753 | ||
| The cancer epidemiology of radiation | Q34342493 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 | ||
| Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). | Q34510187 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours | Q34625316 | ||
| Etiology and management of therapy-related myeloid leukemia | Q34714984 | ||
| Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience | Q34996659 | ||
| Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. | Q35127977 | ||
| Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual | Q35182925 | ||
| The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy | Q35849723 | ||
| Long-term safety of filgrastim (rhG-CSF) administration | Q35894617 | ||
| Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. | Q36103987 | ||
| Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence | Q36204516 | ||
| Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort | Q36949179 | ||
| Therapy-related myeloid leukemia. | Q37009760 | ||
| Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review | Q37729615 | ||
| A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies | Q38323097 | ||
| National trends in prescription drug expenditures and projections for 2014. | Q39240419 | ||
| Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy | Q39785729 | ||
| Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy | Q41442636 | ||
| Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-Medicare. | Q43854246 | ||
| Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience | Q44381560 | ||
| Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome | Q44399078 | ||
| Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. | Q46127853 | ||
| Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors | Q46192794 | ||
| Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group | Q46499711 | ||
| Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide | Q46551686 | ||
| Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study. | Q51284044 | ||
| Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience | Q55240735 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk | Q63365930 | ||
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial | Q66829419 | ||
| Risk of leukemia after chemotherapy and radiation treatment for breast cancer | Q68137055 | ||
| Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia | Q71703134 | ||
| Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia | Q71789713 | ||
| Granulocyte colony stimulating factor does not induce long‐term DNA instability in healthy peripheral blood stem cell donors | Q73285435 | ||
| Secondary leukemias induced by topoisomerase-targeted drugs | Q77333785 | ||
| Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? | Q79735070 | ||
| Myelodysplastic syndromes: incidence and survival in the United States | Q79899691 | ||
| Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia | Q83857369 | ||
| Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients | Q84127237 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| acute myeloid leukemia | Q264118 | ||
| P304 | page(s) | 133-143 | |
| P577 | publication date | 2015-10-08 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer | |
| P478 | volume | 154 |
| Q92001657 | A Case of Therapy-Related Acute Myeloid Leukemia in a Patient With Heterozygous Mutations in the Ataxia Telangiectasia Mutated Gene |
| Q90344532 | A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management |
| Q61807631 | Cancer-associated stroke: Pathophysiology, detection and management (Review) |
| Q52586260 | Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. |
| Q88946019 | Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution |
| Q38930269 | Higher body mass index in 16-19 year-old Jewish Adolescents of North African, Middle Eastern and European Origins is a Predictor of Acute Myeloid Leukemia: a cohort of 2.3 million Israelis |
| Q91881156 | Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States |
| Q89774664 | Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders |
| Q90478489 | Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma |
| Q89397464 | The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression |
Search more.